Tropfer bei Psoriasis

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents. Verbindung der Formel 1: Compound of the formula 1: FORMEL I wobei R 1: Verbindung nach Anspruch 1 der folgenden Formel: The compound of claim 1 of the following formula: Verbindung nach Anspruch 1 der Formel II: A compound according to Tropfer bei Psoriasis 1 of formula II: Iii a five-membered aromatic heterocyclic ring group, such as 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which in addition any combination of one or more substituents such as halogen, an alkyl group of 1 containing up to 10 carbon atoms, trifluoromethyl and alkoxy, can carry.

A compound according to claim 8, wherein X is a substituted alkyl, aryl or heteroaryl group which carries a protruding basic nitrogen functionality represented for example by the structures a shown below to F, wherein the wavy line the point of attachment to the core structure of 11 corresponds to the formula: Verbindung nach Anspruch 8, wobei X Gruppe d ist und R 6 eine 3-Pyridylgruppe ist.

A compound according to claim 8, wherein X is group d and R 6 is a 3-pyridyl group. Verbindung nach Anspruch 8, wobei X Gruppe d ist und R 4 eine Methylgruppe ist.

A compound according to claim 8, wherein X is group d and R 4 is a Tropfer bei Psoriasis group.

Verbindung nach Anspruch 1 oder 8, wobei R 6 eine 3-Pyridylgruppe ist und R 4 eine Methylgruppe ist. A compound according to claim 1 or 8, wherein R 6 is a 3-pyridyl group and R 4 is a Neumyvakin Psoriasis Wasserstoffperoxid group. Verbindung nach Anspruch 8, die folgendes ist: A compound according to claim 8, is the following: A pharmaceutical composition comprising a compound according to any one of claims 1 to A pharmaceutical composition according to claim 19, further comprising a pharmaceutically acceptable carrier.

A pharmaceutical composition according to claim 20, which is formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions. A cosmetic composition for topical administration comprising a compound according to any one of claims 1 to Use of a compound according to any one of claims 1 to 18 for preparing a medicament. Use of a compound according to any one of claims 1 to 18 for preparing a Tropfer bei Psoriasis for treating neoplastic diseases such as mastocytosis, mastocytosis of the dog, gastrointestinal stromal tumor "GIST" in humans, small cell lung cancer, non-small cell lung cancer, acute myeloid leukemia, acute lymphoblastic leukemia, Myelodysplasiesyndrom, Tropfer bei Psoriasis myelogenous leukemia, colorectal carcinoma, gastric carcinoma, gastrointestinal stromal tumors, testicular cancers, glioblastomas and astrocytomas.

Use of a compound according to any one of claims 1 to 18 for preparing a medicament for treating allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite inflammation and infection by blood-sucking parasites.

Use of a compound according to any one of claims 1 to 18 for preparing a medicament for treating inflammatory diseases such as rheumatoid arthritis, conjunctivitis, ankylosing spondylitis, osteoarthritis, gouty arthritis and other Tropfer bei Psoriasis conditions.

Use of Ekzem Medikamente compound according to any one of claims Tropfer bei Psoriasis to 18 for preparing a medicament for treating graft-versus-rust disease or graft Tropfer bei Psoriasis in any organ transplantation including kidney, pancreas, liver, heart, lung and bone marrow.

Insbesondere sind diese Verbindungen potente und selektive c-kit-Inhibitoren. In particular, these compounds are potent and selective c-kit inhibitors. Tyrosine kinases are receptor proteins of the type or non-receptor type, which transfer the terminal phosphate of ATP to tyrosine residues, which signal transduction pathways are activated or deactivated.

Of these proteins is known that they Tropfer bei Psoriasis involved in many cellular mechanisms, which in the case of a breakage disorders such as abnormal cell proliferation and migration as well as inflammation.

Heute gibt es etwa 58 bekannte Rezeptortyrosinkinasen. Today there are about 58 known receptor tyrosine kinases. Andere Tyrosinkinasen sind die wohl bekannten VEGF-Rezeptoren Kim et al.

Other tyrosine kinases are the well-known VEGF receptors Kim et al. Unter Tyrosinkinaserezeptoren ist c-kit Tropfer bei Psoriasis besonderem Interesse. Among Tropfer bei Psoriasis kinase receptors c-kit is of special interest. It was found that mast cells present in gistan Psoriasis Bewertungen of patients, who have the generation of diseases such as autoimmune diseases rheumatoid arthritis, inflammatory bowel diseases inflammatory bowel diseases, IBD allergic diseases, tumor angiogenesis, inflammatory diseases, and interstitial cystitis causes or because are involved.

The c-kit receptor also can be constitutively activated by mutations leading to abnormal proliferation tent and for Tropfer bei Psoriasis development of diseases such as Tropfer bei Psoriasis and various cancers.

For this reason, it has been proposed to targetieren c-kit to deplete the mast cells responsible for these disorders. EP EP. US 5, US 5. US 3, US 3, und and US 4, US 4, und Aryl- und Heteroarylchinazolin And aryl and Heteroarylchinazolin US 5, US 5.

Keine dieser Verbindungen wurde jedoch als potente und selektive Inhibitoren von c-kit oder des c-kit-Wegs. None of these compounds has, however, as a potent and selective inhibitors of c-kit or of the c-kit pathway. In Verbindung mit der vorliegenden Erfindung haben wir festgestellt, dass Verbindungen, die den 2- 3-Aminoaryl aminoarylthiazolen entsprechen, potente und selektive Inhibitoren von c-kit oder c-kit-Weg sind.

In connection with the present invention, we have found that compounds corresponding aminoarylthiazolen the 2- 3-amino aryl Tropfer bei Psoriasis, potent and selective inhibitors of c-kit or c-kit the way.

These compounds are good candidates ASD Fraktion in Psoriasis verwendet treating diseases such as autoimmune diseases, inflammatory diseases, cancer and mastocytosis. The present invention thus relates to compounds which are 4-arylamino-arylthiazolen to the 2- 3-amino.

These compounds this web page signal transduction involving the tyrosine phosphokinase c-kit and mutant forms thereof, selectively inhibit. In a first embodiment the invention relates to compounds of the formula I is aligned, which may represent either free base forms thereof of the substances or pharmaceutically acceptable salts: FORMEL I und wobei R 1: Formula I and wherein R 1: R 6 is one of the following: In another preferred embodiment, click to see more R 1 has the meaning indicated in c shown above, the invention is directed to compounds of the following formula: Among the compounds of formula I, the invention is particularly embodied by the compounds of the following formula II: In einer anderen Alternative kann der Substituent R 6der in Tropfer bei Psoriasis Formel II an Stellung 4 des Thiazolrings angebunden ist, stattdessen Stellung 5 des Thiazolrings belegen.

In another alternative, the substituent R 6, which is connected in the formula II in position 4 of the thiazole ring, instead occupy position 5 of the thiazole ring. Among the preferred more info correspond to formula Tropfer bei Psoriasis, the invention is directed to compounds in which X is a substituted alkyl, aryl or heteroaryl group which carries Tropfer bei Psoriasis protruding basic nitrogen functionality represented for example by the structures a shown below to fwherein the wavy line the point of attachment to the core structure of formula II: Unter den Gruppen a bis f ist X siehe Formel II vorzugsweise Article source d.

Among the groups a to f X see formula II preferably group d. Des Weiteren betrifft die Erfindung unter den bevorzugten Verbindungen der Formel I oder II die Verbindungen, in denen R 2 und R 3 Wasserstoff sind. Furthermore, the invention relates to the preferred compounds of formula I or II compounds in which R 2 and R 3 are hydrogen. Vorzugsweise ist R 4 eine Methylgruppe und R 5 ist H. Preferably, R 4 is a methyl group Tropfer bei Psoriasis R 5 is H.

In addition, R 6 is preferably a 3-pyridyl group see structure g belowor a 4-pyridyl group see structure h below. Die gewellten Linien in den Strukturen g und h entsprechen dem Punkt der Anlagerung an die Kernstruktur von Formel I oder II. The wavy lines in the structures g and h correspond to the point of attachment to the core structure of Formula I or II.

Thus, the invention contemplates the following into consideration: Among the compounds of formula II, the invention is particularly embodied by the compounds wherein R 2, R 3, R Tropfer bei Psoriasis are hydrogen, corresponding to the following formula II N- 3- 4- Pyridinyl thiazolylamino methylphenyl 4-methylpiperazinyl methyl benzamid N- 3- 4- ftorokort Psoriasis Salbe Bewertungen für -thiazolylamino methylphenyl -4 - 4-methylpiperazinyl methyl benzamide.

N-[4-Methyl 4-phenylthiazolylamino phenyl] 4-methylpiperazinylmethyl benzamid N- [4-methyl 4-phenyl-thiazolylamino phenyl] 4-methylpiperazinylmethyl -benzamide.

N-[4-Chlor 4-pyridinylthiazolylamino phenyl] 4-methylpiperazinylmethyl benzamid N- [4-chloro 4-pyridinyl-thiazolylamino phenyl] 4-methylpiperazinylmethyl -benzamide. N-[4-Methyl 4-pyridinylthiazolylamino phenyl]isonicotinamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] isonicotinamide. Among the compounds of formula II, the invention is particularly embodied by the compounds wherein X is a substituted aryl group, which correspond to the N- [3- thiazolylamino -phenyl] -amide family and the following formula II N-[4-Methyl 4-pyridinylthiazolylamino phenyl][3- 4-trifluormethylphenyl ureido]benzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] [3- 4-trifluoromethyl-phenyl Tropfer bei Psoriasis benzamide N-[4-Methyl 4-pyridinylthiazolylamino phenyl] 3-thiophenylureido Tropfer bei Psoriasis N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] 3-thiophenylureido benzamide N-[4-Methyl 4-pyridinylthiazolylamino phenyl] thiophensulfonylamino benzamid N- [4-methyl 4-pyridinyl-thiazolylamino -phenyl] thiophenesulfonylamino -benzamide braunes Pulver Fp.: N-[4-Methyl 4-pyridinylthiazolylamino phenyl]pyridinylbenzamid 8.

N- [4-methyl 4-pyridinyl-thiazolylamino Tropfer bei Psoriasis pyridinyl benzamide gelbes Pulver Fp.: N-[4-Methyl 4-pyridinylthiazolylamino phenyl] 2-morpholinylethoxy benzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] 2-morpholinyl-ethoxy benzamide beigegelbes Pulver Fp.: N-[4-Methyl 4-pyridinylthiazolylamino phenyl]pyridinylbenzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] pyridinyl benzamide braunes Pulver Fp.: N-[4-Methyl 4-pyridinylthiazolylamino phenyl]trifluormethylbenzamid Tropfer bei Psoriasis N- [4-methyl 4-pyridinyl-thiazolylamino -phenyl] trifluoromethylbenzamide Tropfer bei Psoriasis 4-pyridinylthiazolylamino phenyl]pyrrolidinylmethylbenzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] pyrrolidinylmethyl-benzamide Among the compounds of formula II, the invention is particularly embodied by the compounds wherein X is a Psoriasis bei HIV-Infizierten aryl group of the 4- 4-substitutedylmethyl-N- [3- thiazolylamino phenyl] benzamide family and the following formula II-4 correspond to: N-[4-Methyl 4-pyridinylthiazolylamino phenyl]morpholinylmethylbenzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] morpholinylmethyl-benzamide N-[4-Methyl 4-pyridinylthiazolylamino phenyl]piperidinylmethylbenzamid N- [4-methyl 4-pyridinyl-thiazolylamino phenyl] piperidinylmethyl-benzamide N-[4-Methyl 4-pyridinylthiazolylamino phenyl][3- 4-trifluormethylphenyl ureidomethyl]benzamid Among compounds of formula II, the invention is particularly embodied by the compounds wherein X is an aryl group of the 3-disubstituted-amino-N- [3- thiazolylamino -phenyl] -benzamide Tropfer bei Psoriasis and the following formula II -5 meet: N-[4-Methyl 4-pyridinylthiazolylamino phenyl]morpholinylbenzamid N- [4-methyl 4-pyridinyl-thiazolylamino -phenyl] morpholinyl benzamide beigefarbenes Pulver Fp.: Among the compounds of formula II, the http://gl-dd.de/aevitum-fuer-psoriasis.php is particularly embodied by the compounds wherein X is a -OR group, corresponding to the [3- thiazolylamino phenyl] carbamate family and the following formula II In a second embodiment the invention is directed to a method for producing a compound of formula I depicted see more. Dies bedingt die Kondensation eines Substrats der allgemeinen Formel 10 mit einem Thioharnstoff des Typs This involves the condensation of a substrate of the general formula 10 with a thiourea type 11th 11 a: Substituent "L" in formula 10 is a nucleofugic leaving group in nucleophilic substitution reactions L, etc.

Tropfer bei Psoriasis R1 in Formel 11a entspricht Gruppe R1, wie in Formel I beschrieben. Group R1 corresponds to formula 11a group R1, as described click the following article formula I. Group "PG" in formula 11c is a suitable protecting group of a type that is commonly used by a professional.

The reaction of 10 with 1 a-d leads to a thiazole-type product of formula 12a-d. Formel 12a ist mit Formel I identisch. Formula 12 is identical to formula I. Folglich entspricht R1 in 12a R1 in Formel I. Consequently corresponds to R1 in 12a R1 in formula I.

Formula 12b describes a precursor to compounds of formula I, where the substituent R1 is absent. Consequently substituent R1 Tropfer bei Psoriasis connected in a second phase of the synthesis with the free amine group in 12b, leading to the complete structure embodied by formula I: The introduction of R1, the nature of which is Psoriasis ist Rauchen die Wirkung auf described on page 3 for the general formula I, is achieved by application of standard reactions that are well known to the skilled person, such as alkylation, acylation, sulfonylation, formation of ureas, etc.

Formula 12c 12b describes an N-protected variant of compound. Folglich wird Gruppe PG in einer zweiten Phase der Synthese gespalten, um Verbindung 12c in Verbindung 12b umzuwandeln. Group "PG" in formula 12c represents a protecting group of the type represents, which is generally used by Tropfer bei Psoriasis professional. Consequently, group PG is cleaved in a second phase of the synthesis to convert compound 12c in connection 12b.

Compound 12b is then to structures of formula I as described in detail above, further developed. Formel 12d beschreibt ein Nitroanalogon von Verbindung 12b. Formula 12d 12b describes a nitro analogue of compound.

In a second phase of the synthesis, the nitro group of compound 12d is by any of the several methods that are used by the skilled person, reduced to produce the corresponding amino group, namely compound 12b.

The compound thus obtained is subsequently 12b to structures of formula I as described in detail above, further developed. Beispiele der Verbindungssynthese Examples of the compound synthesis. All chemicals used were commercial products for analysis. Dimethylformamide DMFmethanol MeOH were of anhydrous commercial grade and were used without further purification.

Dichlormethan und Tetrahydrofuran THF wurden vor Gebrauch unter click the following article Argonstrom frisch destilliert.

Dichloromethane and tetrahydrofuran THF were freshly distilled prior to link under a stream of argon. The progress of the reactions was analyzed by thin layer chromatography Tropfer bei Psoriasis precoated silica gel 60F with Fluka TLC Psoriasis Wodka, which were visualized under UV light.

Multiplicities in 1 H-NMR Spekren be as singlet sbroad singlet br sdoublet dtriplet tquadruplet qand multiplet m is displayed, and the NMR spectrum was measured on a MHz Bruker spectrometer performed. Dieses Material kann aus Methanol und Ether umkristallisiert werden. This material may be recrystallized from methanol and ether. Methyl-[4- 1-N-methylpiperazino methyl]benzoat Methyl [4- 1-N-methylpiperazino methyl] benzoate.

The reaction mixture was stirred at room temperature for 1 hour. After slow addition of sodium cyanoborohydride 2 g, 32 mmolthe solution overnight at room temperature was allowed to stir. Diese Extrakte wurden verworfen. These extracts were discarded. The aqueous phase was then basified by addition of aqueous 2. The mixture was concentrated in vacuo and the residue was dissolved Tropfer bei Psoriasis ml ethyl acetate.

This organic phase was 2 x ml washed with water 1 x mL and brine, dried over MgSO 4 and concentrated under reduced pressure. The mixture was heated to reflux for 15 min, then was the hydrobromide salt of 2-methyltert-butoxycarbonylaminoanilin 8. Nach 1 Tropfer bei Psoriasis wurde das Reaktionsgemisch in Eiswasser ml gegossen und der hellgelbe Niederschlag wurde mittels Filtration isoliert.

Learn more here 1 hour, the reaction mixture was poured into ice water mL and the bright yellow precipitate was isolated by filtration. This crude solid was then heated for 45 min in 70 ml of 2.

The mixture was cooled and basified link ammonium hydroxide. The precipitate of crude thiourea was recovered by filtration and dissolved in ml of ethyl acetate.

The organic phase was washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure. Ein Gemisch von 3-Bromacetylpyridin-HBr-Salz 0,81 g, 2,85 mmolN- 2-Methyltert.

A mixture of 3-Bromacetylpyridin-HBr salt 0. The mixture was visit web page, filtered removal of KHCO3 and evaporated under reduced pressure. The residue was dissolved in CHCl 3 40 mL and washed with saturated aqueous sodium bicarbonate solution and with water. The organic layer was dried over Na 2 SO 4 and concentrated. The solution was stirred for 2 hours at room temperature, then evaporated under reduced pressure.

The residue was dissolved in ethyl acetate. This crude product was used directly in the next step. A 2M-solution of trimethylaluminum in toluene 2. The mixture was warmed to room temperature and stirred for 30 min at room temperature. A solution of methyl 4- 1-N-methylpiperazino methyl benzoate 0. The mixture was extracted with dichloromethane 3 x 20 ml. The combined organic layers were washed with brine 3 x 20 ml and dried over anhydrous MgSO 4.

In a third embodiment, the invention relates to a pharmaceutical compound comprising a compound as depicted above. Such a pharmaceutical composition may take the form of a pharmaceutical composition adapted for oral administration and prepared using pharmaceutically acceptable carriers that are well known in the art, can be formulated in suitable doses.

Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable excipients consisting of a vehicle and auxiliaries, which facilitate processing of the active compounds into preparations which can be used pharmaceutically.

Tropfer bei Psoriasis Zusammensetzung der Erfindung kann auch die Form einer pharmazeutischen oder kosmetischen Zusammensetzung zur topischen Verabreichung annehmen. The composition of the invention may also take the form of a pharmaceutical or cosmetic composition for topical administration. Diese Zusammensetzungen werden nach Standardverfahren hergestellt.

These compositions are prepared according to standard procedures. The composition of the invention comprises any ingredient commonly used in dermatology and Tropfer bei Psoriasis. It may comprise at least one ingredient selected from hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, emollients, viscosity enhancing polymers, humectants, surfactants, preservatives, antioxidants, solvents, and fillers, antioxidants, solvents, fragrances, fillers, light stabilizers, bactericides, odor absorbers and colorants is selected.

As oils which can be used in the invention, mineral oils liquid paraffinvegetable oils liquid fraction of shea butter, Tropfer bei Psoriasis oilanimal oils, synthetic oils, silicone oils cyclomethicone and fluorinated oils may be mentioned.

Fatty alcohols, fatty acids stearic acid and waxes paraffin, carnauba, beeswax may also Tropfer bei Psoriasis used as fatty substances. As hydrophilic active agents, proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, Tropfer bei Psoriasis and sugar derivatives, vitamins, starch and plant extracts, in Tropfer bei Psoriasis those to be used by Aloe Vera. As lipophilic active ingredients essential fatty acids, ceramides and essential oils may retinol vitamin A and its derivatives, tocopherol vitamin E and its derivatives, may be used.

These agents add-giving or skin when using additional moisture smoothing features. In addition, a surfactant may be incorporated into the composition to provide a deeper penetration of the compound capable of Tropfer bei Psoriasis mast cells, such as a tyrosine kinase inhibitor, preferably a c-kit inhibitor.

Cohesion agents selected for example from the group consisting of polyisobutylene, polyvinyl Tropfer bei Psoriasis and polyvinyl alcohol, and thickening agents. Chemical methods for conveying the topical absorption of drugs are well known in the art. An Electrometric Study", J. An Electro Metric Study" Physiochemical Aspects", Surfactant Tropfer bei Psoriasis Series, Bd. MM Reiger Marcel Dekker, Inc.

And decylmethylsulfoxide DL Sekura and J. Scala, "The Percutaneous Tropfer bei Psoriasis of alkylmethyl sulfide," Pharmacology of the Skin, Advances in Biology of Skin, Appleton-Century Craft Vol. It was observed that increasing the polarity of the head group in amphoteric molecules increases their penetration-enhancing properties, but with the disadvantage of increasing their skin irritating properties ER Cooper and B. Berner, "Interaction of Surfactants with Epidermal Tissues: Physical Chemical Aspects, "Surfactant Science Series, Vol.

A second Tropfer bei Psoriasis of chemical enhancers are generally referred to as co-solvents. These materials are relatively easily absorbed topically and Tropfer bei Psoriasis for some medicines by a variety of mechanisms promoting permeation. Are a few examples of compounds which have shown an ability for promoting the absorption of various compounds. The pharmaceutical compositions of Tropfer bei Psoriasis invention may also be designed for administration with aerosolized formulation to target areas of the respiratory tract of a patient.

Formulations are preferably solutions, eg. For example aerosolized wie den auf sieht Es Foto Anfangsstadium aus Psoriasis Händen a pharmaceutically active drugs for inhalation and a Tropfer bei Psoriasis active carrier for inhalation z.

Die Erfindung umfasst die in The invention includes the Tropfer bei Psoriasis US 5, US 5, beschriebenen Systeme: Accordingly, the pharmaceutical preparation according to the invention is prepared such that the active substance is dissolved or dispersed in a suitable nontoxic medium and said solution or dispersion atomized to an aerosol, ie is extremely finely dispersed in a carrier gas.

This is for example in the form of an aerosol propellant gas containers, pump sprays or other per se known devices for liquid misting and solid misting, especially the accurate individual dosage technically possible.

Folglich ist die Erfindung auch auf Aerosolvorrichtungen, die die wie oben Tropfer bei Psoriasis Verbindung und eine solche Formulierung, umfassen, vorzugsweise mit Dosierventilen, ausgerichtet. Accordingly, the invention is also directed to aerosol devices comprising the compound as visit web page above and such a formulation, preferably with metered aligned.

The pharmaceutical compositions of the invention may be also intended for intranasal administration. In this regard, one of ordinary skill in the art will just appreciate pharmaceutically acceptable carriers for administering the compound to the nasal mucous membrane surfaces. The choice of appropriate carriers depends on the particular mode of administration that is contemplated. For administration upper the upper respiratory tract, the composition can be a solution, for. Example, water or isotonic saline, buffered or unbuffered, or be formulated as a suspension, for intranasal Tropfer bei Psoriasis as drops or as a spray.

Preferably, such solutions or suspensions are isotonic relative to nasal secretions and have approximately the same pH, the z. Puffer sollen physiologisch kompatibel sein und beinhalten, lediglich beispielhaft, Phosphatpuffer. Buffer should be physiologically compatible and include, merely by way of example, phosphate buffer.

For example, a representative nasal decongestant is used as the buffered to a pH of about 6. To conventional intranasal carriers, including Nasengele, creams, pastes or ointments with a viscosity of, for.

Example, from about Tropfer bei Psoriasis to about cps or from about 2, to 6, cP or more, may also be used to a longer lasting Contact to deliver with nasal surfaces. Eine bevorzugte Alkylcellulose ist z. A preferred alkylcellulose is, for. Example, methylcellulose in a concentration ranging from about 5 to about or more mg per ml of carrier. A more preferred concentration of methyl cellulose is, simply by way of example, from about 25 to about mg per ml of carrier.

Further constituents such as known in the art preservatives, colorants, lubricants or viscous mineral or Psoriasis essen mit oils, perfumes, natural or synthetic plant Tropfer bei Psoriasis such as aromatic oils, and humectants and viscosity-increasing agent such. For nasal administration of solutions or suspensions of the invention are in the art, various devices Tropfer bei Psoriasis the generation of drops, droplets and sprays available.

A dispenser for dispensing a previously metered unit dose, which contains a dropper or a spray Tropfer bei Psoriasis, the or containing a solution or suspension for delivery as drops or as a spray is prepared containing one or more doses of the drug to be administered and is a Another object of the invention.

Ein weiterer Aspekt der Erfindung ist auf die Verwendung der Verbindung zum Herstellen eines Arzneimittels ausgerichtet. Another aspect of the invention is directed to the use of the compound for preparing a check this out. In other words, the invention encompasses a method of treating a disease that is related to unregulated c-kit transduction, the method comprising administering an effective amount of a compound as defined above to a mammal in need of such treatment.

In particular, the invention features a method for treating a disease is aligned consisting of autoimmune diseases, allergic diseases, bone loss, cancers such as leukemia and GIST, tumor angiogenesis, inflammatory diseases, inflammatory bowel diseases inflammatory bowel diseases, IBDinterstitial cystitis, mastocytosis, infections diseases, metabolic diseases, is fibrosis, diabetes and CNS disorders selected, the method comprising administering an effective Tropfer bei Psoriasis of a compound depicted above to a mammal juckende Leiste need of such treatment.

The compounds Tropfer bei Psoriasis above are suitable for Tropfer bei Psoriasis manufacture of a medicament for the treatment of diseases related to unregulated c-kit transduction, including, but not limited to: See more and cardiovascular disease. In dieser Hinsicht umfasst die Erfindung die Verwendung der oben definierten Verbindungen zum Herstellen eines Arzneimittels oder einer kosmetischen Zusammensetzung zum Bleichen menschlicher Haut.

In this regard, the invention encompasses the use of compounds as defined above for Tropfer bei Psoriasis a medicament or a cosmetic composition for whitening human skin. In view of mastocytosis, the invention contemplates the use of compounds as defined above for treating the different categories which can be Tropfer bei Psoriasis as follows: Die Kategorie I setzt sich aus zwei Unterkategorien IA und IB zusammen.

The category I is composed of two sub-categories IA and IB. Kategorie IA besteht aus Erkrankungen, in denen die Mastzelleninfiltration strikt auf die Haut begrenzt ist. Category IA consists of diseases in which mast cell infiltration is strictly limited to the skin. This category is the most common form of the disease is and includes: Diese Formen zeichnen sich durch ihre hervorragende Tropfer bei Psoriasis mit spontanen Remissionen in Kinder und einem sehr indolenten Verlauf in Volksheilmittel für Psoriasis mit Teer. These forms are characterized by their excellent prognosis with spontaneous remissions in children and a very Tropfer bei Psoriasis course in adults.

The long-term survival of this form of disease is generally comparable with that of the normal population and the transfer in another form of mastocytosis is rare. Kategorie IB wird von indolenter systemischer Erkrankung SM mit oder ohne Hautbeteiligung dargestellt. Category IB is represented by indolent systemic disease SM with or without skin involvement.

These forms are much more common than in children in adults. The course of the disease is often indolent, but sometimes signs of aggressive or malignant mastocytosis can occur, leading to progressive impaired organ function. The category gegenereerde rheumatoider Psoriasis kann includes mastocytosis with an associated hematologic disorder such as myeloproliferative or Myelodysplastiesyndrom or acute leukemia.

Tropfer bei Psoriasis malignant mastocytosis affects not usually affect the skin. The progress of the disease depends generally on Tropfer bei Psoriasis type of associated hematological disorder that determines the prognosis. The category III is represented by aggressive systemic mastocytosis with a Tropfer bei Psoriasis infiltration of multiple organs is common by abnormal mast cells. In Patienten, die dieser Art aggressiven klinischen Verlaufs nachgehen, sind Peripherblutmerkmale, die auf eine myeloproliferative Erkrankung hinweisen, markanter.

In patients who pursue this kind of aggressive clinical course, are peripheral blood features suggestive of a myeloproliferative disorder, distinctive. The progress of the disease can be very rapid, similar to acute leukemia, or some patients can show a longer survival time.

This unit probably represents the rarest type of leukemia in humans and has a very poor prognosis, similar to the rapidly progressing variant of malignant mastocytosis. Basophilic leukemia can either de novo or act as the final http://gl-dd.de/schuppenflechte-auf-der-koerpersolarium.php of urticaria pigmentosa or systemic mastocytosis. The invention also contemplates the method as Tropfer bei Psoriasis for the treatment of recurrent bacterial infections, infections occurring again after asymptomatic periods such as bacterial cystitis.

In particular the invention for treating FimH expressing bacteria infections can be exerted, as Gram-negative enterobacteria including E. In diesem Verfahren zum Behandeln von bakterieller Infektion ist eine getrennte, aufeinander folgende oder gleichzeitige More info von mindestens einem Antibiotikum aus Bacitracin, den Cephalosporinen, den Penicillinen, den Aminoglycosiden, den Tetracyclinen, den Streptomycinen und den Makrolid-Antibiotika, wie Erythromycin; In this method for treating bacterial infection is a separate, sequential or simultaneous administration of at least one antibiotic is selected from bacitracin, the cephalosporins, the penicillins, the aminoglycosides, the tetracyclines, the Streptomycinen and the macrolide antibiotics such as erythromycin; den Fluorochinolonen, Actinomycin, den Sulfonamiden und Trimethoprim, von Interesse.

In a preferred embodiment, the invention features a method for treating neoplastic disease such as mastocytosis, mastocytosis of the dog, gastrointestinal stromal tumor "GIST" of the people, small cell lung cancer, non-small cell lung cancer, acute myeloid leukemia, acute lymphoblastic leukemia, Myelodysplasiesyndrom, chronic myelogenous leukemia, colorectal carcinomas, gastric carcinomas, gastrointestinal stromal tumors, testicular cancers, glioblastomas and astrocytomas, aligned, the method requires the administration of a composition as defined herein compound to a human or mammal, especially dogs and cats, the or the one such treatment includes.

In another preferred embodiment, the invention features a method for treating allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite inflammation and infection by blood-sucking parasites, aligned, the method comprises administering a compound as defined herein to a human or mammal, especially dogs and cats, or the need of such treatment.

Tropfer bei Psoriasis yet another preferred embodiment, the invention features a method for treating inflammatory Tropfer bei Psoriasis such as rheumatoid arthritis, conjunctivitis, ankylosing spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, aligned, the method comprising administering a composition as defined herein compound to a human, in need of such treatment, comprising.

In yet another preferred embodiment, the invention features a method for treating graft-versus-rust disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung and bone marrow, aligned, the method comprising administering a compound as defined herein to a human in need of such treatment comprising.

In vitro TK inhibition assays. Experiments were performed using purified intracellular domain of c-kit expressed in baculovirus performed. The evaluation of the kinase activity was measured by the phosphorylation of tyrosine, the target peptide containing assessed using an established ELISA assay assessed. Weitere Versuche nicht gezeigt zeigen, dass mindestens eine Verbindung als perfekte kompetitive Inhibitoren von ATP wirkt.

Further experiments not shown indicate that at least one compound acts as perfect competitive inhibitors of ATP. Ex vivo TK inhibition assays. Cells were washed twice in PBS before they were plated at 5 x Tropfer bei Psoriasis 4 cells per well of well plates in triplicate and either with hematopoietic growth factors hematopoietic Tropfer bei Psoriasis factors, HGF or without stimulation. After 2 days of culture, 37 Bq 1. Cells were harvested and filtered through glass fiber filters and the incorporation of [3 H] thymidine was measured in a scintillation counter.

Overactive Psoriasis Gerben var dilutions in Tropfer bei Psoriasis were made before each experiment. Dissolved in DMSO drug cultivation were added at the beginning. Control cultures were prepared by appropriate dilutions of DMSO. Die FMA3- und PZelllinien sind Mastozytomzellen, die Tropfer bei Psoriasis mutierte Formen von kit exprimieren, dh eine Rasterdeletion in der kodierenden Region muriner Juxtamembran der Rezeptorkodone bis The FMA3- and P cell lines are mastocytoma cells expressing endogenous mutated forms of Kit, ie a Rasterdeletion in the murine juxtamembrane coding region of the Rezeptorkodone to The Tropfer bei Psoriasis leukemia-MC line HMC-1 expresses mutations JM-VG.

For each assay, 5. The cell lysates were incubated with a read more immune serum anti-mouse-KIT, which is directed against the cytoplasmic domain of KIT, immunoprecipitated Rottapel et al. Western blot described in the paragraph relating to antibodies either with the 4G10 anti-phosphotyrosine antibody UBI or with the rabbit immune serum anti-mouse-KIT or with different antibodies hybridized.

The membrane was then incubated either with HRP-conjugated goat anti-mouse IgG antibody or with HRP-conjugated goat anti-rabbit IgG antibody ImmunotechProteins of interest were then purified by incubation with ECL reagent Amersham made visible. The experimental results for various compounds according to Tropfer bei Psoriasis invention using the above-described protocols are set forth in Tropfer bei Psoriasis 2.

Mice were irradiated with T-1 5 Gy. Tumorzellen 10 6 wurden subkutan an To gepfropft. Tumor cells 10 6 were injected subcutaneously grafted to To. Tumor size was measured daily by T The number of surviving mice was Tropfer bei Psoriasis daily. In this experimental model, the tumor size at T14 is about 20 mm 3. The mice were in advance over two days day -2, day -1 before induction of Tropfer bei Psoriasis with the compound of formula II-3 2 x, Arthritis was induced by intraperitoneal injection of ul serums at days 0 and 2.

The treatment with the compound 2x, The ankle thickness and arthritis score was evaluated for 15 days. Two sets of experiments were carried out with different numbers of mice, one with 4 mice, the other with 8 mice. At Tropfer bei Psoriasis end of the experiment the hind limbs were collected. Treated mice with a Psoriasis Ursache Arthritis of formula II-3in comparison to the control of a significant reduction in tumor size in T30 and T A compound of formula II-3 has demonstrated significant activity in the in vivo mouse model of arthritis.

Die Ergebnisse sind in den The results are shown in 1 1. Legenden der Figuren Figure legends. CAA1CACCNACNCDED1EPA1EPB1USUSUSUSUSUSUSUSWOA1. Marco CiufoliniBruno GiethlenAlain MoussyCamille Wermuth. BiBTeXEndNoteRefMan. In-vitro-Inhibitonsassay-Ergebnisse In vitro results Inhibitonsassay.


Verbindungen der allgemeinen Formel III Compounds of the general formula III wobei R 1 -OR a, -NR a R b, -CR c R d R e, CO 2 R a oder -C(O)NR a R b ; wherein R 1.

Damit kann das Arzneimittel mit dem Wirkstoff Dimethylfumarat in allen EU-Staaten sowie in Island und Norwegen auf den Markt kommen. Hersteller Almirall teilte mit, dass […]. Wenn es um Schuppenflechte geht, ist es manchmal nicht lecker.

Bei dem Thema muss und kann nicht immer alles cool oder locker sein. Aber manches, das will man gar nicht so genau wissen, oder? Oft beginnt die Schuppenflechte am Tropfer bei Psoriasis. Manchmal bleibt dies auch die einzige Stelle, an der die Erkrankung auftritt.

Ein paar Schuppen fallen vielleicht Tropfer bei Psoriasis nicht so auf — aber die Psoriasis breitet sie sich gern […]. Wer Schuppenflechte hat, sollte im Prinzip ein Freund des Lichts sein: Wir haben uns click the following article der Schuppenflechte juckt nicht so stark.

Regividerm — ein Krimi um eine Creme? Andauernde Hilfe gegen Schuppenflechte. Behandlung der Psoriasis mit Cremes und Salben. Diese Website ist von der Stiftung Health On the Net zertifiziert. Skilarence zugelassen und bald auf dem Markt Fans wollten Schuppen von Liam Gallagher Hautprobleme am Kopf — Psoriasis oder nicht?

Diese App zeigt die Wirkung von Sonne und Solarium 4. Cosentyx und Taltz bestehen vor strengem Expertengremium 2. Tropfer bei Psoriasis Scanner Tropfer bei Psoriasis unter die Schuppenflechte Beliebte Artikel Regividerm — ein Krimi um eine Creme?

Andauernde Hilfe gegen Schuppenflechte 7. Behandlung der Psoriasis mit Cremes und Salben 4.


CBD Cannabidiol From Industrial Hemp For Plaque Psoriasis Relief And Cure

Related queries:
- Psoriasis Vietnam
Try the new Google Patents, Rhinitis, Konjunktivitis, Ekzem, Psoriasis oder Aerosols oder Schaumaufsprühens); Tropfer -Anwendung (wie beispielsweise bei Ohr.
- Psoriasis und Lavendel
Bernd Kardorff. Gesunde Haut. 2. AufJage Springer Berlin Heidelberg New York Hongkong London Mailand Paris Tokio Bernd Kardorff. esunde au Ratgeber von A.
- Psoriasis pustulosa, palmoplantar
Psoriasis ist eine häufige Hauterkrankung, dass Psoriasis -Läsionen bei Personen, • Bewerben Teebaumöl mit einem Tropfer jeden Tag für Kopfhaut ringworm.
- Psoriasis AIDS
Augentropfen (Lösung von 0, 25%). 1 ml enthält 2, 5 mg Wirkstoff. Die Tropfer, Psoriasis, Mykosen, Ekzemen; Bei der Anwendung von Chloramphenicol bei.
- zur Behandlung von Psoriasis Plantar
ich persönlich empfehlen eine ebaron Tropfer PROI hörte nur gute was bei der Einrichtung der einfachen Einstiegs Stereo- oder Surround.
- Sitemap


Comments are closed.